ClinicalTrials.gg
TerminatedNCT00576901Updated Aug 11, 2014Results posted

A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.

A Phase 2 interventional study of bevacizumab [Avastin] and Docetaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Terminated at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-11.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
The sample for statistical analysis of results could not be recruited within the specified timeframe upon retirement of the original principal investigator.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
207th of 248
23 · median 68
Started
2007
with 18 others
Phase 2
157 of 264
11 open now
Registered
145th of 264
by date
Lead sponsor
16 of 264
Hoffmann-La Roche

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 207th largest by enrollment of the 248 interventional ones that give a count, is one of 19 that started in 2007, is one of 157 in phase 2, and was the 145th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This single arm study will assess the efficacy and safety of combination first-line treatment with docetaxel + Xeloda + Avastin in patients with inflammatory or locally advanced breast cancer. Patients will receive 3-weekly cycles of Avastin (15mg/kg i.v. on day 1 of each cycle), docetaxel (75mg/m2 i.v. on day 1 of each cycle, after Avastin) and Xeloda (2000mg/m2 p.o. on days 1-15 of each cycle). Four cycles of chemotherapy are planned, plus an optional additional two cycles; after chemotherapy patients will be assessed for surgery. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients, >=18 years of age;
  • -negative, locally advanced (stage II or III) or inflammatory cancer of the breast;
  • performance status 0-1.

Exclusion criteria

Exclusion Criteria:

  • disease (stage IV);
  • previous treatment for breast cancer;
  • evidence of ;
  • current or recent (within 10 days of first dose of Avastin) use of aspirin (>325mg/day) NSAIDs or full dose anticoagulants for therapeutic purposes;
  • cardiovascular disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: Docetaxel · Drug: Xeloda

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Pathological Complete Response (pCR)

    pCR was defined as the absence of viable tumor cells, as determined by standard histologic procedure, in the tumor specimen (including regional lymph nodes) obtained at surgery. In order to minimize evaluation bias, tumor specimens were analyzed by both a central and local pathologist. The number of participants with pathological tumor stage 0 (pT0) and regional lymph nodes stage 0 (pN0) at surgery was determined. pCR was defined as the number of participants with pT0 and pN0 at surgery divided by the total number of participants with pathological tumor stage data collected.

    Time frame: At time of surgery, after receiving up to 6 cycles of treatment (average of 12 to 18 weeks)

Secondary outcomes

  1. Percentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)

    The percentage of participants with a best overall response of CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]). No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short aixs was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Day 1 of Cycles 1-6

  2. Progression-Free Survival

    Progression-free survival was defined as the time from the date of informed consent until the date disease progression was identified, or the date of death from disease progression, whichever occurred first.

    Time frame: Cycles 1-6

  3. Overall Survival

    Overall survival was defined as the time from the date of informed consent until the date of death due to any cause.

    Time frame: Cycles 1-6

  4. Percentage of Participants Undergoing Breast-Conserving Surgery

    The percentage of participants who were able to undergo breast-conserving surgical procedures (segmentectomy plus lymphadenectomy or quadrantectomy plus lymphadenectomy) rather than non-breast conserving procedures (radical mastectomy or modified-radical mastectomy) following 4 or more treatment cycles.

    Time frame: Following Cycle 6

07

Results

Posted Aug 11, 2014

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab+Docetaxel+Capecitabine
Started23
Completed20
Not completed3
Withdrew: Withdrawal by subject1
Withdrew: Disease course1
Withdrew: Protocol violation1

Outcome measures

PrimaryPercentage of Participants Achieving Pathological Complete Response (pCR)

pCR was defined as the absence of viable tumor cells, as determined by standard histologic procedure, in the tumor specimen (including regional lymph nodes) obtained at surgery. In order to minimize evaluation bias, tumor specimens were analyzed by both a central and local pathologist. The number of participants with pathological tumor stage 0 (pT0) and regional lymph nodes stage 0 (pN0) at surgery was determined. pCR was defined as the number of participants with pT0 and pN0 at surgery divided by the total number of participants with pathological tumor stage data collected.

Time frame:
At time of surgery, after receiving up to 6 cycles of treatment (average of 12 to 18 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pathological Complete Response (pCR)
percentage of participantsBevacizumab+Docetaxel+Capecitabine
Percentage of Participants Achieving Pathological Complete Response (pCR)0
SecondaryPercentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)

The percentage of participants with a best overall response of CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]). No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short aixs was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Day 1 of Cycles 1-6
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)
percentage of participantsBevacizumab+Docetaxel+Capecitabine
Percentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)80
SecondaryProgression-Free Survival

Progression-free survival was defined as the time from the date of informed consent until the date disease progression was identified, or the date of death from disease progression, whichever occurred first.

Time frame:
Cycles 1-6

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival was defined as the time from the date of informed consent until the date of death due to any cause.

Time frame:
Cycles 1-6

No measurements were reported for this outcome.

SecondaryPercentage of Participants Undergoing Breast-Conserving Surgery

The percentage of participants who were able to undergo breast-conserving surgical procedures (segmentectomy plus lymphadenectomy or quadrantectomy plus lymphadenectomy) rather than non-breast conserving procedures (radical mastectomy or modified-radical mastectomy) following 4 or more treatment cycles.

Time frame:
Following Cycle 6
Reported as:
Number · percentage of participants
Percentage of Participants Undergoing Breast-Conserving Surgery
percentage of participantsBevacizumab+Docetaxel+Capecitabine
Percentage of Participants Undergoing Breast-Conserving Surgery26.09

Adverse events

Collected over Throughout study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab+Docetaxel+Capecitabine—2/23 (8.7%)23/23 (100%)
Most frequent serious events
Most frequent serious events
EventBevacizumab+Docetaxel+Capecitabine
NeutropeniaBlood and lymphatic system disorders1/23
Disease progressionGeneral disorders1/23
Most frequent other events
Showing 10 of 29
Most frequent other events
EventBevacizumab+Docetaxel+Capecitabine
StomatitisGastrointestinal disorders14/23
Hand-foot syndromeSkin and subcutaneous tissue disorders14/23
NeutropeniaBlood and lymphatic system disorders11/23
AlopeciaSkin and subcutaneous tissue disorders9/23
DiarrhoeaGastrointestinal disorders9/23
NauseaGastrointestinal disorders8/23
AstheniaGeneral disorders6/23
VomitingGastrointestinal disorders5/23
Mucous membrane inflammationGeneral disorders5/23
EpistaxisRespiratory, thoracic and mediastinal disorders4/23

Baseline characteristics

Intent-to-treat (ITT) population. The ITT population included all enrolled participants.

Age, Continuous
Age, Continuous(years)Bevacizumab+Docetaxel+Capecitabine
Mean51.96 ± 11.51
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab+Docetaxel+Capecitabine
Female23
Male0
08

Study locations

1 site
  • Madrid, 28041, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2007
First posted
Dec 19, 2007
Start
Nov 2007
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Aug 11, 2014
Last update
Aug 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00576901
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 19, 2007
Start date
Nov 2007
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Aug 11, 2014
Last update
Aug 11, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Capecitabine

Start the discussion